Omnicell (NASDAQ:OMCL) Releases Earnings Results

Omnicell (NASDAQ:OMCL) posted its quarterly earnings results on Thursday. The company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.42 by $0.16, Briefing.com reports. Omnicell had a return on equity of 5.66% and a net margin of 3.13%. The business’s revenue was down .9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.51 EPS.

Here are the key takeaways from Omnicell’s conference call:

• Third-quarter results exceeded guidance, with revenue of $308 million and non-GAAP EBITDA of $45 million, supported by favorable product mix, gross margins, disciplined spending, and cost efficiencies.
• Omnicell raised full-year 2026 non-GAAP EBITDA guidance to $187 million–$193 million and EPS guidance to $2.48–$2.56, while narrowing revenue and ARR ranges because of improved visibility.
• The company said the Titan XT and OmniSphere pipeline grew modestly and became more mature, with Titan XT shipments beginning shortly and OmniSphere general availability still targeted for the first half of 2027. Management views OmniSphere subscriptions as a potentially high-margin, incremental revenue stream over time.
• Product bookings remain heavily back-end weighted, and management cited the timing of medium and large health-system decisions, competitive deal outcomes, and lengthy implementation cycles as sources of quarter-to-quarter variability.
• Second-half memory and component costs are expected to reduce margins by roughly $6 million, with about half incurred in the third quarter and the remainder expected in the fourth quarter; policy changes surrounding the 340B program are also expected to have a modest impact on 2026 ARR.

Omnicell Trading Up 2.6%

Shares of OMCL traded up $0.93 during trading on Thursday, reaching $36.88. 841,709 shares of the company traded hands, compared to its average volume of 642,003. The stock has a 50-day simple moving average of $34.57 and a 200-day simple moving average of $39.26. The stock has a market cap of $1.68 billion, a PE ratio of 43.91, a price-to-earnings-growth ratio of 0.95 and a beta of 0.98. Omnicell has a twelve month low of $30.69 and a twelve month high of $55.00. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13.

Wall Street Analysts Forecast Growth

OMCL has been the topic of a number of analyst reports. Zacks Research raised shares of Omnicell from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. Piper Sandler reissued an “overweight” rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. KeyCorp restated an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Weiss Ratings raised shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Finally, Wells Fargo & Company decreased their price objective on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.86.

Key Omnicell News

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Omnicell reported third-quarter adjusted earnings of $0.58 per share, exceeding the $0.42 analyst consensus and improving from $0.51 a year earlier. GAAP net income also doubled to $11 million, or $0.24 per diluted share. Omnicell Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Third-quarter revenue of $307.9 million was broadly in line with expectations, while service revenue increased to $134.8 million from $133.1 million, indicating continued demand for recurring services. Omnicell Announces Third Quarter 2026 Financial Results
• Neutral Sentiment: Management updated full-year 2026 guidance to revenue of $1.225 billion-$1.231 billion, non-GAAP EBITDA of $187 million-$193 million and non-GAAP EPS of $2.48-$2.56. Cash and equivalents totaled $314.9 million at quarter-end. Omnicell Provides Fourth-Quarter and Full-Year Guidance
• Negative Sentiment: Revenue declined approximately 1% year over year, led by product revenue falling to $173.1 million from $177.5 million. Fourth-quarter revenue guidance of $295 million-$301 million reportedly came in below analyst expectations, raising concerns about near-term growth. Omnicell Exceeds Q3 Expectations but Revenue Guidance Misses
• Negative Sentiment: Recent insider activity was entirely selling, including transactions by CEO Randall Lipps and other executives. While not necessarily a direct reflection of operating performance, the activity may weigh on sentiment. Omnicell Reports Third-Quarter Revenue and Net Income

About Omnicell

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.